% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Ballhausen:304245,
      author       = {A. Ballhausen and F. Morano and A. Stahler and S. Lonardi
                      and A. J. Kind and C. Cremolini and S. Swoboda and G. Randon
                      and D. Horst and M. Prisciandaro and A. H. S. Alig and C. C.
                      Pircher and A. Jarosch and P. Andena and A. Kurreck and A.
                      A. Chiaramonte and S. Stintzing$^*$ and F. Pietrantonio and
                      D. P. Modest$^*$ and A. Raimondi},
      title        = {{P}rimary tumor sidedness and negative hyperselection to
                      modulate anti-{EGFR}-based maintenance strategies in
                      patients with {RAS} wild-type metastatic colorectal cancer:
                      individual patient data pooled analysis of two randomized
                      clinical trials.},
      journal      = {British journal of cancer},
      volume       = {nn},
      issn         = {0007-0920},
      address      = {Edinburgh},
      publisher    = {Nature Publ. Group},
      reportid     = {DKFZ-2025-01799},
      pages        = {nn},
      year         = {2025},
      note         = {epub},
      abstract     = {Patients with RAS wild-type (WT), left-sided metastatic
                      colorectal cancer (mCRC), negatively hyperselected for
                      anti-EGFR resistance alterations, benefit most from
                      anti-EGFR-based first-line treatment. The predictive impact
                      of these stratification parameters on maintenance strategy
                      efficacy is unclear.This pooled analysis included individual
                      patient data from the PanaMa (NCT01991873) and Valentino
                      (NCT02476045) phase 2 trials. Patients with RAS WT mCRC
                      received FOLFOX plus Panitumumab induction therapy followed
                      by maintenance with 5-fluorouracil/leucovorin (5-FU/LV) plus
                      Panitumumab vs. 5-FU/LV monotherapy (PanaMa) or Panitumumab
                      monotherapy (Valentino). Outcomes included progression-free
                      survival (PFS) and overall survival (OS). Subgroup analyses
                      examined primary tumor sidedness (left vs. right) and
                      hyperselection status (negative vs. altered).Among 607
                      patients receiving induction, sidedness and hyperselection
                      status were available for 589 and 511 patients,
                      respectively. Left-sided and negative hyperselected tumors
                      were observed in $80.2\%$ and $63.9\%$ of patients,
                      respectively. Panitumumab-based maintenance improved PFS in
                      left-sided, negative hyperselected patients compared to
                      5-FU/LV alone, with no OS differences. PFS and OS were
                      comparable for Panitumumab alone vs. Panitumumab plus
                      5-FU/LV.Tumor sidedness and hyperselection status
                      significantly influence maintenance strategy efficacy in
                      mCRC. For left-sided, negative hyperselected patients,
                      Panitumumab monotherapy may optimize efficacy while
                      minimizing toxicity. Further investigation into the relative
                      contribution of individual hyperselection parameters in this
                      setting is warranted.},
      cin          = {BE01},
      ddc          = {610},
      cid          = {I:(DE-He78)BE01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40877636},
      doi          = {10.1038/s41416-025-03164-5},
      url          = {https://inrepo02.dkfz.de/record/304245},
}